Comparison
Efinopegdutide vs. Maridebart Cafraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
2055640-93-0
no data
Molecular weight
no data
no data
Half-life
115 h
no data
Sequence
modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)no data
Mechanism of action
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
3
1
of which in humans
3
1
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Efinopegdutide and Maridebart Cafraglutide?
- Efinopegdutide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Efinopegdutide or Maridebart Cafraglutide?
- The highest available evidence level is "Human RCT" for Efinopegdutide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Efinopegdutide and Maridebart Cafraglutide in Germany and the United States?
- Germany: Efinopegdutide — Unapproved, Maridebart Cafraglutide — Unapproved. United States: Efinopegdutide — Unapproved, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.